ArticleScientific reports2021
Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 32 citations in OpenAlex.
- Serum FGF-23 and α-Klotho Levels in Prolactinoma and Non-Tumoral Hyperprolactinemia: An Exploratory Cross-Sectional Comparative Study.Diagnostics (Basel, Switzerland) · 2026Article
- Does persistent hyperprolactinemia contribute to bone loss independently of estrogen deficiency in postmenopausal women?Pituitary · 2026Article
- Osteometabolic complications in patients with secreting pituitary adenomas: Is there an impact of gender?Pituitary · 2026Review
- Prolactinoma-associated headache: Clinical and radiological correlates and long-term outcomes.Pituitary · 2026Article
- Linking the relationship between drug-induced osteoporosis and the gut microbiota.Frontiers in endocrinology · 2026Review
- Predictors of favorable long-term outcomes in first-line surgery for microprolactinomas.Journal of neuro-oncology · 2025Article
- Gender differences in prolactin thresholds and their association with lactotroph adenoma invasiveness for potential treatment considerations.Scientific reports · 2025Article
- Navigating prognostic strategies for GH- and PRL-secreting pituitary neuroendocrine tumors: key insights from a clinicopathological study.Frontiers in endocrinology · 2025Article
- The Association Between Antipsychotics and Bone Fragility: An Updated Comprehensive Review.Diagnostics (Basel, Switzerland) · 2024Review
- Modern approach to bone comorbidity in prolactinoma.Pituitary · 2024Review
- Review
- Review
- Characteristics and outcomes of men with erectile dysfunction as the presenting symptom due to a lactotroph adenoma.Acta neurochirurgica · 2024Article
- The diagnostic yield of inferior petrosal sinus sampling in Cushing syndrome in the era of ovine CRH shortage.Acta neurochirurgica · 2024Article
- Commentary: Clinical characteristics of male prolactinoma patients mainly presenting with severe obesity and the metabolic response to dopamine agonist therapy.Frontiers in endocrinology · 2024Article
- Prolactin-secreting pituitary adenomas: male-specific differences in pathogenesis, clinical presentation and treatment.Frontiers in endocrinology · 2024Review
- Gender-specific prolactin thresholds to determine prolactinoma size: a novel Bayesian approach and its clinical utility.Frontiers in surgery · 2024Article
- Prolactinomas in adolescent and elderly patients-A comparative long-term analysis.Frontiers in surgery · 2023Article
- Postcraniotomy Headache: Etiologies and Treatments.Current pain and headache reports · 2022Review
- Machine Learning for Outcome Prediction in First-Line Surgery of Prolactinomas.Frontiers in endocrinology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While prolactinoma patients have high bone turnover, current data are inconclusive when it comes to determining whether correction of hyperprolactinemia and associated hypogandism improves osteodensitometric data in men and women over the long term. In a large cohort of including 40 men and 60 women, we studied the long-term impact of prolactinoma treatment on bone mineral density (BMD) in men versus women, assessed adverse effects of a primary surgical or medical approach, and evaluated data for risk factors for impaired BMD at last follow-up using multivariate regression analyses. Median duration of follow-up was 79 months (range 13-408 months). Our data indicate that the prevalence of impaired BMD remained significantly higher in men (37%) than in women (7%, p < 0.001), despite the fact that hyperprolactinemia and hypogonadism are under control in the majority of men. We found that persistent hyperprolactinemia and male sex were independent risk factors for long-term bone impairment. Currently, osteoporosis prevention and treatment focus primarily on women, yet special attention to bone loss in men with prolactinomas is advised. Bone impairment as "end organ" reflects the full range of the disease and could become a surrogate marker for the severity of long-lasting hyperprolactinemia and associated hypogonadism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.